A rheumatological immunological administration device

Abstract

The application belongs to the field of medical auxiliary instruments, in particular to a rheumatism and immunology disease administration device, which comprises an auxiliary sleeve, a stay seat is arranged in the middle of the auxiliary sleeve, a top block is fixedly connected to the upper portion of the auxiliary sleeve, the top block is used for controlling the stay seat to be pushed out downward, an injection needle is arranged at the bottom of the stay seat, a communicating device for communicating with the injection needle is arranged at the top of the stay seat, an adding base is arranged at the bottom of the auxiliary sleeve, a sticking sheet is placed on the upper portion of the adding base, and a connecting ring is attached to the top surface of the sticking sheet by the edge. Through the arrangement, the function of periodic subcutaneous injection administration at different parts is realized, the effect of long-term subcutaneous injection administration can be achieved only by once needle-piercing operation, the pain and psychological burden caused by each needle-piercing during subcutaneous injection administration are reduced, the administration enthusiasm of patients is improved, meanwhile, the operation is simple, and one person can complete the operation independently without going to the hospital for treatment.

Description

Technical Field

[0001] This invention belongs to the field of medical auxiliary devices, specifically a drug delivery device for rheumatic and immune diseases. Background Technology

[0002] Rheumatic immune diseases are chronic systemic autoimmune diseases in which the immune system mistakenly attacks its own tissues, causing inflammation and damage to joints, muscles, bones, and other parts of the body. Long-term, standardized treatment is required to control the disease and improve prognosis.

[0003] Drug treatment for rheumatic and immunological diseases requires individualized and long-term management. Core drugs include antirheumatic drugs, biologics, and targeted therapies to improve the condition, aiming to suppress abnormal immune responses, control inflammation, and prevent tissue damage. Oral medications are the most commonly used and basic. Topical application is used to treat the "skin manifestations" of the disease or relieve local symptoms. Subcutaneous injection has become a very important treatment method, even the main one, because oral medications are easily broken down and rendered ineffective by the digestive tract. Subcutaneous injection is the most effective and reliable, and is suitable for severe patients.

[0004] Traditional subcutaneous injection devices are often simple syringes. Each subcutaneous injection requires enduring puncture pain, causing psychological burden and leading to patient resistance, which affects the treatment process. Furthermore, subcutaneous injection is inconvenient to operate alone, which is even more unfriendly to the elderly. Since many patients with rheumatic and immune diseases are elderly, this further affects the treatment effect.

[0005] Therefore, the present invention provides a drug delivery device for rheumatic immune diseases. Summary of the Invention

[0006] In order to overcome the shortcomings of the prior art, at least one technical problem raised in the background art is solved.

[0007] The technical solution adopted by the present invention to solve its technical problem is as follows: The present invention provides a drug delivery device for rheumatic and immune diseases, including an auxiliary sleeve, a stop seat provided in the middle of the auxiliary sleeve, a top block fixedly connected to the upper part of the auxiliary sleeve, the top block being used to control the stop seat to be pushed downward, an injection needle provided at the bottom of the stop seat, a communicating device for communicating with the injection needle being installed at the top of the stop seat, an adding base provided at the bottom of the auxiliary sleeve, an adhesive sheet placed on the top of the adding base, a connecting ring being attached to the top surface of the adhesive sheet near the edge, and the connecting ring being connected to the bottom of the auxiliary sleeve; This setup enables periodic subcutaneous injection at different sites, allowing for long-term subcutaneous drug administration with a single injection. This reduces the pain and psychological burden associated with each injection, increasing patient willingness to receive medication. The procedure is simple and can be performed independently by one person without the need for hospitalization. Furthermore, it allows for subcutaneous injections at multiple sites, and two injection sites can be placed simultaneously for alternating injections. This reduces the risk of prolonged injections in one location, which can lead to subcutaneous fat cell hypertrophy, proliferation, and fibrosis, hindering drug absorption.

[0008] Preferably, the auxiliary sleeve has two sets of binding plates fixed inside, both sets of binding plates are arranged in a ring, the binding plates are made of elastic material, the top surface of the connecting ring has multiple mating holes, and the bottom of the auxiliary sleeve has multiple mating blocks that are adapted to the mating holes. During operation, when fixing a new stop seat, simply push the stop seat into the interior of the auxiliary sleeve from the bottom. After passing through one set of elastic material binding plates, the stop seat will be clamped in the auxiliary sleeve by the two sets of binding plates, waiting for the subsequent ejection operation. The connecting ring needs to be pressed against the top of the adhesive piece at the beginning to ensure the adhesion strength. As the mating blocks are inserted into the mating holes, the auxiliary sleeve is pulled out at the same time, which can pull out the adhesive piece and leave the protective film at the bottom in the addition base.

[0009] Preferably, the top of the top platform is equipped with a control button and a filling valve, and the bottom of the top platform is fixedly connected to two jet nozzles. The edge of the stop seat is movably fitted against the inner wall of the auxiliary sleeve. The outer side of the auxiliary sleeve has multiple side grooves, in which an injection tube is placed. During operation, when a puncture is required, after the auxiliary sleeve is fixed to the skin, pressing the control button releases the internal air pressure of the top platform, spraying a high-speed airflow from the bottom of the jet nozzles, allowing the injection needle to be quickly inserted into the body. Afterwards, removing the auxiliary sleeve leaves the stop seat and adhesive patch on the skin. The bottom diameter of the stop seat is approximately five centimeters, which will not affect normal human activity. When medication is required, only... The injection tube needs to be removed from the side slot and connected to the communicating vessel. The communicating vessel connects to the injection needle. The injection tube has two layers: one filled with medication and the other with high pressure. When connected, the medication is pushed outward and injected subcutaneously into the body through the injection needle. The injection process can be slow, and the injection tube can be placed on the communicating vessel for a long time without affecting normal physiological activities. This ensures that the medication is slowly released into the patient's body. After release, the tube can be removed. The communicating vessel is a one-way channel, so removal will not affect backflow or other issues. A new injection tube can be directly replaced for the next injection. Because it is a subcutaneous injection, even with a simple operation, it will not cause significant damage to the body, ensuring safety.

[0010] Preferably, the injection needle includes a metal tube and a needle tube wrapped around the outside of the metal tube. A protective sleeve is threaded to the bottom of the stop seat, and the protective sleeve is located outside the needle tube. The stop seat is provided with a drive wheel for pulling the needle tube upward. During operation, to ensure stable insertion of the injection needle, the recommended needle tube, including the metal tube, is used. The needle tube is responsible for puncture during insertion, and after puncture, the needle tube is pulled outward by the drive wheel. The metal tube is elastic and has an internal channel, so even if the human body is engaged in vigorous activity, the elastic metal tube can bend appropriately, reducing foreign body sensation and stinging sensation, and improving the user experience. To ensure hygiene and safety, the protective sleeve can protect the injection needle from external influences before use. The G-value of the metal tube can be 31G, with a diameter of 0.25 mm, which is a common standard for insulin and biological inhibitors. This makes the internal space of the metal tube smaller, which not only has less impact on the human body, but also, since it is a subcutaneous injection, the air carried during injection will not affect the human body.

[0011] Preferably, the needle tube has an opening on its outer side, a pointed bottom that extends beyond the bottom of the metal tube, and the outer side of the drive wheel is in contact with the outer side of the needle tube. The top of the needle tube extends to the top of the resting seat. During operation, the needle tube has an opening on its side, allowing the metal tube to be fixed to the internal device of the resting seat from the side, maintaining the vertical position of the metal tube after the needle tube is withdrawn. The needle tube can be pulled out vertically by the rotational friction of the drive wheel, without manual operation, which is quick and convenient.

[0012] Preferably, a storage box is fixedly connected inside the stop seat, and the outside of the storage box is connected to the metal tube through multiple pipes. A squeezing plate that can be translated is provided on the other side of the needle tube. During operation, the storage box and pipes fix the vertical state of the metal tube. The squeezing plate can maintain the state of the needle tube when it moves upward and maintain the state of the metal tube after the needle tube is removed.

[0013] Preferably, the storage box is filled with liquid, and the metal tube has a hollow design that runs vertically through it, with multiple grooves on its surface. During operation, to reduce the body's rejection of the metal tube, a mixture of glucocorticoid aqueous solution and immunosuppressant aqueous solution is filled into the storage box. Because this mixture comes into contact with the surface of the metal tube through the tube, and because the surface of the metal tube has multiple grooves, the mixture will slowly fill the area around the metal tube under capillary action. It can directly act on the surrounding immune cells, effectively inhibiting local inflammation and fibrosis without causing systemic side effects, and no manual intervention is required, ensuring a suitable environment for long-term use of the device.

[0014] Preferably, a sliding lock box is fixedly connected inside the stop seat. Multiple sliding rods are slidably connected to one end of the sliding lock box facing the needle tube. The sliding rods are fixedly connected to the squeezing plate, and an auxiliary frame is fixedly connected to the top of the sliding rods. The auxiliary frame is drivenly connected to the bottom of the drive wheel and slidably connected to the top of the storage box and the sliding lock box. During operation, when the needle tube is pulled out, the drive wheel is started first. The drive wheel simultaneously comes into contact with the auxiliary frame and the outside of the needle tube. Under the action of friction, the needle tube moves upward. At the same time, the auxiliary frame and the squeezing plate move towards the storage box. The squeezing plate will squeeze the needle tube first, but the curvature of the two is not matched, and the contact surface is small, so it will not affect the needle tube to continue to move upward. When the needle tube is pulled out, the squeezing plate continues to move and will come into contact with the metal tube. At this time, the sliding rod slides to the limit position. The sliding lock box contains an elastic element to block the sliding rod when it slides to the limit, so that it cannot move. In this way, the metal tube will be restricted by the tube and the squeezing plate, keeping it in a vertical state, while allowing the needle tube to be pulled out smoothly.

[0015] Preferably, the top surface of the stop seat has a slot, in which a power box for controlling the rotation of the drive wheel is placed. A protrusion to assist in removal is fixed to the top of the stop seat. Two sealing plates are slidably connected to the top surface of the stop seat. During operation, after the needle is successfully removed, the power box can be pulled out and installed on another stop seat, which saves costs. At the same time, after the power box is removed, the sealing plates are used to seal the exposed part to reduce environmental interference.

[0016] Preferably, the communicating vessel is rotatably connected to the top surface of the stop seat, and an injection valve is fixedly connected to the top surface of the communicating vessel. A docking valve for communicating with a metal tube is fixedly connected to the bottom surface of the injection valve. During operation, after the needle is pulled out, the communicating vessel can be rotated above the metal tube and pressed down to connect its end with the metal tube. At the same time, a sealing plate is used to fix the end of the communicating vessel to complete the seal. By connecting the injection tube with the injection valve, slow drug delivery can be completed.

[0017] The beneficial effects of this invention are as follows: 1. The rheumatic immune disease drug delivery device of the present invention, through the setting of the stop seat, realizes the function of periodic subcutaneous injection at different sites. Only one injection operation is needed to achieve the effect of long-term subcutaneous injection, reducing the pain and psychological burden caused by each injection, improving the patient's willingness to take the drug. At the same time, the operation is simple and can be completed by one person independently without going to the hospital for treatment. Moreover, subcutaneous injection can be performed at multiple required sites, and the stop seat can be placed at two sites on the body at the same time to alternate the injection, reducing the problem of long-term drug injection in one place, which can cause subcutaneous fat cell hypertrophy, hyperplasia and fibrosis, and affect drug absorption.

[0018] 2. The rheumatoid and immunological drug delivery device of the present invention, when puncture is required, only requires waiting for the auxiliary sleeve to be fixed to the skin, and then pressing the control button to release the internal air pressure of the top block, spraying a high-speed airflow from the bottom of the jet head, allowing the injection needle to be quickly inserted into the body. Afterwards, the auxiliary sleeve is removed, leaving the stop seat and adhesive patch on the skin. The bottom diameter of the stop seat is about five centimeters, which will not affect the normal activities of the person. When drug delivery is required, simply take out the injection tube from the side groove, connect the injection tube to the communicating vessel, and the communicating vessel is connected to the injection needle. At the same time, the injection tube has two layers, one layer filled with liquid medicine and the other layer with high air pressure. When connected, the liquid medicine will be pushed outward and injected subcutaneously into the human body through the injection needle. The injection process can be carried out slowly, and the injection tube can be placed on the communicating vessel for a long time without affecting normal physiological activities, ensuring that the drug is slowly released into the patient's body. Attached Figure Description

[0019] The invention will now be further described with reference to the accompanying drawings.

[0020] Figure 1 This is a perspective view of the present invention; Figure 2 This is a three-dimensional view of the structure of the present invention; Figure 3 This is a cross-sectional perspective view of the present invention; Figure 4 This is a cross-sectional view of the stop seat of the present invention; Figure 5 This is a perspective view of the storage box and sliding lock box of the present invention; Figure 6 This is a perspective view of the auxiliary frame and metal tube of the present invention; Figure 7 This is a schematic diagram of the top surface structure of the stop seat of the present invention; In the diagram: 1. Auxiliary sleeve; 2. Adding base; 3. Side groove; 4. Injection tube; 5. Top platform block; 6. Control button; 7. Filling valve; 8. Restraint plate; 9. Dwelling seat; 10. Interlocking block; 11. Connecting ring; 12. Adhesive plate; 13. Interlocking hole; 14. Protective sleeve; 15. Air nozzle; 16. Communicating device; 17. Storage box; 18. Slide lock box; 19. Injection needle; 20. Metal tube; 21. Needle tube; 22. Squeezing plate; 23. Slide rod; 24. Power box; 25. Drive wheel; 26. Injection valve; 27. Sealing plate; 28. Auxiliary frame. Detailed Implementation

[0021] To make the technical means, creative features, objectives and effects of this invention easier to understand, the invention will be further described below in conjunction with specific embodiments.

[0022] like Figures 1 to 7As shown in the figure, an embodiment of the present invention provides a drug delivery device for rheumatic and immune diseases, including an auxiliary sleeve 1. A stop seat 9 is provided in the middle of the auxiliary sleeve 1. A top platform block 5 is fixedly connected to the upper part of the auxiliary sleeve 1. The top platform block 5 is used to control the stop seat 9 to push downward. An injection needle 19 is provided at the bottom of the stop seat 9. A communicating device 16 for communicating with the injection needle 19 is installed at the top of the stop seat 9. An adding base 2 is provided at the bottom of the auxiliary sleeve 1. An adhesive sheet 12 is placed on the top of the adding base 2. A connecting ring 11 is attached to the top surface of the adhesive sheet 12 near the edge. The connecting ring 11 is connected to the bottom of the auxiliary sleeve 1. In use, pull the base 2 out from the bottom of the auxiliary sleeve 1. At this time, the adhesive patch 12 and the connecting ring 11 will remain at the bottom of the auxiliary sleeve 1. Hold the auxiliary sleeve 1 and attach it to the location where the medication needs to be injected. The bottom of the adhesive patch 12 is sticky. Originally attached to the bottom of the base 2, it will stick to the skin as it is attached to the body. The top block 5 can quickly push the stop seat 9 downward by spraying a high-speed airflow or other common ejection mechanism. The bottom surface of the adhesive patch 12 has a needle hole in the middle for the injection needle 19 to pass through. After the injection needle 19 passes through the needle hole, the bottom surface of the stop seat 9 will adhere to the top surface of the adhesive patch 12. The adhesive patch 12 is sticky on both sides. The injection needle 19 is then inserted into the dermis. The auxiliary sleeve 1 is removed, leaving the connecting ring 11 on the auxiliary sleeve 1. The stop seat 9 remains on the skin along with the adhesive patch 12. When subcutaneous injection is needed, the required vial is aligned with the communicating vessel 16 on the top surface of the stop seat 9, allowing the medication to be slowly injected into the dermis. This completes the injection. Multiple injections can be performed within one cycle. After one cycle, the stop seat 9 is removed. One cycle typically lasts about twelve days. Before the next cycle begins, a new adhesive patch 12 is placed in the addition base 2. The new adhesive patch 12 has protective films on both sides. The inner bottom of the base 2 also has adhesive. Before aligning the base 2 with the auxiliary sleeve 1, remove the protective film from the top surface of the adhesive patch 12. Simultaneously, detach the previous connecting ring 11 from the auxiliary sleeve 1 and attach it to the top surface of the connecting ring 11. Secure the new stop seat 9 into the auxiliary sleeve 1. Align the auxiliary sleeve 1 with the base 2, allowing the connecting ring 11 to align with the auxiliary sleeve 1. Then pull up the auxiliary sleeve 1. Because the bottom of the base 2 is attached to the bottom protective film of the adhesive patch 12, the protective film will be removed during separation. At this point, the bottom of the adhesive patch 12 can adhere smoothly to the skin. Repeat the above-mentioned pin-adhesion operation to apply the patch to different parts of the body. The device leaves a stop seat 9 at the injection site for drug administration. This design enables periodic subcutaneous injection at different sites, allowing for long-term subcutaneous drug administration with just one injection. This reduces the pain and psychological burden associated with each injection, increasing patient willingness to receive medication. The procedure is simple and can be performed independently by one person without the need for hospitalization. Furthermore, it allows for subcutaneous injection at multiple sites, and the stop seat 9 can be placed at two different locations simultaneously for alternating injections. This reduces the risk of prolonged injection in one location, which can lead to subcutaneous fat cell hypertrophy, proliferation, and fibrosis, hindering drug absorption.

[0023] The auxiliary sleeve 1 has two sets of binding plates 8 fixedly connected inside. Both sets of binding plates 8 are arranged in a ring. The binding plates 8 are made of elastic material. The top surface of the connecting ring 11 has multiple mating holes 13. The bottom of the auxiliary sleeve 1 has multiple mating blocks 10 that are adapted to the mating holes 13. During operation, when fixing the new stop seat 9, simply push the stop seat 9 into the interior of the auxiliary sleeve 1 from the bottom. After passing through a set of elastic material restraint pieces 8, the stop seat 9 will be clamped in the auxiliary sleeve 1 by the two sets of restraint pieces 8, waiting for the subsequent ejection work. At the beginning, the connecting ring 11 needs to be pressed against the top of the adhesive piece 12 to ensure the adhesive strength. As the insertion block 10 and the insertion hole 13 are inserted, the auxiliary sleeve 1 is pulled out at the same time, which can pull out the adhesive piece 12 and leave the protective film at its bottom in the addition base 2.

[0024] The top of the top platform 5 is equipped with a control button 6 and a filling valve 7. Two jet nozzles 15 are fixedly connected to the bottom of the top platform 5. The edge of the stop seat 9 is movably fitted with the inner wall of the auxiliary sleeve 1. Multiple side grooves 3 are opened on the outer side of the auxiliary sleeve 1, and an injection tube 4 is placed in the side grooves 3. During operation, when a puncture is required, simply wait for the auxiliary sleeve 1 to be fixed to the skin, then press the control button 6 to release the internal air pressure of the top block 5. This releases a high-speed airflow from the bottom of the jet nozzle 15, allowing the injection needle 19 to quickly insert into the body. Afterward, remove the auxiliary sleeve 1, leaving the stop seat 9 and adhesive patch 12 on the skin. The bottom diameter of the stop seat 9 is approximately five centimeters, which will not affect normal human movement. When medication is required, simply remove the injection tube 4 from the side groove 3, connect the injection tube 4 to the communicating vessel 16, which connects the communicating vessel 16 to the injection needle 19, and simultaneously... The device has two internal layers: one filled with medication and the other with high pressure. When connected, the medication is pushed outward and injected subcutaneously into the body through the injection needle 19. The injection process can be slow, and the injection tube 4 can be placed on the communicating vessel 16 for a long time without affecting normal physiological activities. This ensures that the medication is slowly released into the patient's body. After release, the tube can be removed. The communicating vessel 16 is a one-way channel, so removal will not affect backflow or other issues. It can also be replaced with a new injection tube 4 for the next injection. Because it is a subcutaneous injection, even with a simple operation, it will not cause significant damage to the body, ensuring safety.

[0025] The injection needle 19 includes a metal tube 20 and a needle tube 21 wrapped around the outside of the metal tube 20. The bottom of the stop seat 9 is threaded with a protective sleeve 14, which is located outside the needle tube 21. The stop seat 9 is provided with a drive wheel 25 for pulling the needle tube 21 upward. During operation, to ensure stable insertion of the injection needle 19, the recommended needle tube 21, including the metal tube 20, is used. The needle tube 21 is responsible for puncture during insertion, and after puncture, the needle tube 21 is pulled outward via the drive wheel 25. The metal tube 20 is elastic and has an internal channel, so even during vigorous activity, the elastic metal tube 20 can bend appropriately, reducing foreign body sensation and stinging, thus improving the user experience. To ensure hygiene and safety, a protective sleeve 14 protects the injection needle 19 from external influences. The metal tube 20 can have a G-value of 31G and a diameter of 0.25 mm, which is a common standard for insulin and biological inhibitors. This results in a smaller internal space for the metal tube 20, minimizing its impact on the human body. Furthermore, any air carried during injection, due to subcutaneous injection, will not affect the body.

[0026] The needle tube 21 has an opening on its outer side, and the bottom of the needle tube 21 has a pointed angle that extends beyond the bottom of the metal tube 20. The outer side of the drive wheel 25 is in contact with the outer side of the needle tube 21, and the top of the needle tube 21 extends through to the top of the rest seat 9. During operation, the needle tube 21 has an opening on the side, allowing the metal tube 20 to be fixed to the internal device of the stop seat 9 from the side, keeping the metal tube 20 in a vertical position after the needle tube 21 is withdrawn. Through the rotational friction of the drive wheel 25, the needle tube 21 can be pulled out vertically without manual operation, which is quick and convenient.

[0027] The storage box 17 is fixedly connected inside the rest seat 9. The outside of the storage box 17 is connected to the metal tube 20 through multiple pipes. The other side of the needle tube 21 is provided with a squeezing plate 22 that can be moved horizontally. During operation, the metal tube 20 is kept vertical by the storage box 17 and the pipe. The extrusion plate 22 can maintain the state of the needle tube 21 when it moves upward, and maintain the state of the metal tube 20 after the needle tube 21 is removed.

[0028] The storage box 17 is filled with liquid, and the metal tube 20 has a hollow design that runs through the top and bottom, and the surface of the metal tube 20 has multiple ridges and grooves. During operation, to reduce the body's rejection of the metal tube 20, a mixture of glucocorticoid aqueous solution and immunosuppressant aqueous solution is filled in the storage box 17. Since this mixture comes into contact with the surface of the metal tube 20 through the pipe, and the surface of the metal tube 20 has multiple grooves, the mixture will slowly fill the area around the metal tube 20 under capillary action. It can directly act on the surrounding immune cells, effectively inhibiting local inflammation and fibrosis without causing systemic side effects, and no manual intervention is required, thus ensuring the long-term operation environment of the equipment.

[0029] The inside of the rest seat 9 is fixedly connected to a sliding lock box 18. Multiple sliding rods 23 are slidably connected to one end of the sliding lock box 18 facing the needle tube 21. The sliding rods 23 are fixedly connected to the extrusion plate 22. An auxiliary frame 28 is fixedly connected to the top of the sliding rods 23. The auxiliary frame 28 is drivenly connected to the bottom of the drive wheel 25. The auxiliary frame 28 is slidably connected to the top of the storage box 17 and the sliding lock box 18. During operation, as the needle 21 is being pulled out, the drive wheel 25 is activated first. The drive wheel 25 simultaneously contacts the auxiliary frame 28 and the outer side of the needle 21. Under friction, the needle 21 moves upward. At the same time, the auxiliary frame 28 and the squeezing plate 22 move towards the storage box 17. The squeezing plate 22 will squeeze the needle 21 first, but the curvatures of the two are not matched, and the contact surface is small, so it will not affect the needle 21 from continuing to move upward. After the needle 21 is pulled out, the squeezing plate 22 continues to move and will contact the metal tube 20. At this time, the slide bar 23 slides to its limit position. The slide lock box 18 contains an elastic element to block the slide bar 23 when it slides to its limit, preventing it from moving. In this way, the metal tube 20 will be restricted by the tube and the squeezing plate 22, keeping it in a vertical state, while allowing the needle 21 to be pulled out smoothly.

[0030] The top surface of the stop seat 9 is provided with a slot, in which a power box 24 for controlling the rotation of the drive wheel 25 is placed. A protrusion for assisting removal is fixed to the top of the stop seat 9, and two closed plates 27 are slidably connected to the top surface of the stop seat 9. During operation, once the syringe 21 is successfully pulled out, the power box 24 can be pulled out and installed on another rest seat 9, which saves costs. At the same time, after pulling out the power box 24, the leaking part is sealed with the sealing plate 27 to reduce environmental interference.

[0031] The communicating vessel 16 is rotatably connected to the top surface of the stop seat 9. An injection valve 26 is fixedly connected to the top surface of the communicating vessel 16. A docking valve for communicating with the metal tube 20 is fixedly connected to the bottom surface of the end of the injection valve 26. During operation, after the needle 21 is pulled out, the connector 16 can be rotated above the metal tube 20 and pressed down to connect its end to the metal tube 20. At the same time, the end of the connector 16 is fixed with the sealing plate 27 to complete the seal. By connecting the injection tube 4 to the injection valve 26, the slow drug delivery can be completed.

[0032] During operation, the base 2 is pulled out from the bottom of the auxiliary sleeve 1. At this time, the adhesive patch 12, together with the connecting ring 11, remains at the bottom of the auxiliary sleeve 1. Holding the auxiliary sleeve 1, the user applies it to the area where medication needs to be injected. The bottom of the adhesive patch 12 is sticky; originally attached to the bottom of the base 2, it adheres to the skin as it comes into contact with the body. The top block 5 can quickly push the stop seat 9 downwards by spraying high-speed airflow downwards or using other common ejection mechanisms. The bottom surface of the adhesive patch 12 has a needle hole in the center for the injection needle 19 to pass through. After the injection needle 19 passes through the needle hole, the bottom surface of the stop seat 9 will adhere to the top surface of the adhesive patch 12. The adhesive patch 12 is sticky on both sides. The injection needle 19 is then inserted into the dermis. The auxiliary sleeve 1 is removed, leaving the connecting ring 11 on the auxiliary sleeve 1. The stop seat 9 remains on the skin along with the adhesive patch 12. When subcutaneous injection is needed, the required vial is aligned with the communicating vessel 16 on the top surface of the stop seat 9, allowing the medication to be slowly injected into the dermis. This completes the injection. Multiple injections can be performed within one cycle. After one cycle, the stop seat 9 is removed. One cycle typically lasts about twelve days. Before the next cycle begins, a new adhesive patch 12 is placed in the addition base 2. The new adhesive patch 12 has protective films on both sides. The inner bottom of the base 2 also has adhesive. Before aligning the base 2 with the auxiliary sleeve 1, remove the protective film from the top surface of the adhesive patch 12. Simultaneously, detach the previous connecting ring 11 from the auxiliary sleeve 1 and attach it to the top surface of the connecting ring 11. Secure the new stop seat 9 into the auxiliary sleeve 1. Align the auxiliary sleeve 1 with the base 2, allowing the connecting ring 11 to align with the auxiliary sleeve 1. Then pull up the auxiliary sleeve 1. Because the bottom of the base 2 is attached to the bottom protective film of the adhesive patch 12, the protective film will be removed during separation. At this point, the bottom of the adhesive patch 12 can adhere smoothly to the skin. Repeat the above-mentioned pin-adhesion operation to apply the patch to different parts of the body. The device leaves a stop seat 9 at the injection site for drug administration. This design enables periodic subcutaneous injection at different sites, allowing for long-term subcutaneous drug administration with just one injection. This reduces the pain and psychological burden associated with each injection, increasing patient willingness to receive medication. The procedure is simple and can be performed independently by one person without the need for hospitalization. Furthermore, it allows for subcutaneous injection at multiple sites, and the stop seat 9 can be placed at two different locations simultaneously for alternating injections. This reduces the risk of prolonged injection in one location, which can lead to subcutaneous fat cell hypertrophy, proliferation, and fibrosis, hindering drug absorption.

[0033] When fixing the new stop seat 9, simply push the stop seat 9 into the interior of the auxiliary sleeve 1 from the bottom. After passing through a set of elastic material restraint pieces 8, the stop seat 9 will be clamped in the auxiliary sleeve 1 by the two sets of restraint pieces 8, waiting for the subsequent ejection work. At the beginning, the connecting ring 11 needs to be pressed against the top of the adhesive piece 12 to ensure the adhesive strength. As the insertion block 10 and the insertion hole 13 are inserted, the auxiliary sleeve 1 is pulled out at the same time, which can pull out the adhesive piece 12 and leave the protective film at its bottom in the addition base 2.

[0034] When a puncture is required, simply wait for the auxiliary sleeve 1 to be fixed to the skin, then press the control button 6 to release the internal air pressure of the top block 5. A high-speed airflow will then be ejected from the bottom of the jet nozzle 15, allowing the injection needle 19 to quickly insert into the body. Afterwards, remove the auxiliary sleeve 1, leaving the stop seat 9 and adhesive patch 12 on the skin. The bottom diameter of the stop seat 9 is approximately five centimeters, which will not affect normal movement. When medication is required, simply remove the injection tube 4 from the side groove 3, connect the injection tube 4 to the communicating vessel 16, which connects to the injection needle 19. Simultaneously, the inside of the injection tube 4... The device consists of two layers: one filled with medication and the other under high pressure. When connected, the medication is pushed outwards and injected subcutaneously into the body through the injection needle 19. The injection process can be slow, and the injection tube 4 can be placed on the communicating vessel 16 for an extended period without affecting normal physiological activities. This ensures the medication is slowly released into the patient's body. After release, the tube can be removed. The communicating vessel 16 is a one-way channel, so removal will not affect backflow or other issues. A new injection tube 4 can be directly replaced for the next injection. Because it is a subcutaneous injection, even with a simple operation, it will not cause significant damage to the body, ensuring safety.

[0035] To ensure stable insertion of the injection needle 19, the recommended needle tube 21, including the metal tube 20, is used. During insertion, the needle tube 21 is responsible for puncture. After puncture, the needle tube 21 is pulled outward by the drive wheel 25. The metal tube 20 is flexible and has an internal channel, so even during vigorous activity, the flexible metal tube 20 can bend appropriately, reducing foreign body sensation and stinging pain, and improving the user experience. To ensure hygiene and safety, the protective cover 14 protects the injection needle 19 from external influences. The metal tube 20 can have a G value of 31G and a diameter of 0.25 mm, which is a common standard for insulin and biological inhibitors. This makes the internal space of the metal tube 20 smaller, which not only has less impact on the human body, but also ensures that any air carried during injection will not affect the human body, since it is a subcutaneous injection.

[0036] The needle tube 21 has an opening on the side, allowing the metal tube 20 to be fixed to the internal device of the stop seat 9 from the side, keeping the metal tube 20 in a vertical position after the needle tube 21 is withdrawn. Through the rotational friction of the drive wheel 25, the needle tube 21 can be pulled out vertically without manual operation, which is quick and convenient.

[0037] The metal tube 20 is fixed in a vertical position by the storage box 17 and the pipe. The extrusion plate 22 can maintain the state of the needle tube 21 when the needle tube 21 moves upward, and maintain the state of the metal tube 20 after the needle tube 21 is removed.

[0038] To reduce the body's rejection of the metal tube 20, a mixture of glucocorticoid aqueous solution and immunosuppressant aqueous solution is filled in the storage box 17. Since this mixture comes into contact with the surface of the metal tube 20 through the pipe, and the surface of the metal tube 20 has multiple grooves, the mixture will slowly fill the area around the metal tube 20 under capillary action. It can directly act on the surrounding immune cells, effectively inhibiting local inflammation and fibrosis without causing systemic side effects, and no manual intervention is required, thus ensuring a suitable environment for long-term use of the device.

[0039] During the removal of the needle 21, the drive wheel 25 is activated first. The drive wheel 25 simultaneously contacts the auxiliary frame 28 and the outer side of the needle 21. Under the action of friction, the needle 21 moves upward. At the same time, the auxiliary frame 28 and the squeezing plate 22 move towards the storage box 17. The squeezing plate 22 will squeeze the needle 21 first, but the curvature of the two is not matched and the contact surface is small, so it will not affect the needle 21 from continuing to move upward. After the needle 21 is removed, the squeezing plate 22 continues to move and will contact the metal tube 20. At this time, the slide bar 23 slides to the limit position. The slide lock box 18 has an elastic element inside, which is used to block the slide bar 23 when it slides to the limit, so that it cannot move. In this way, the metal tube 20 will be restricted by the tube and the squeezing plate 22, keeping it in a vertical state, while allowing the needle 21 to be removed smoothly.

[0040] After the syringe 21 is successfully pulled out, the power box 24 can be pulled out and installed on another rest seat 9, which saves costs. At the same time, after the power box 24 is pulled out, the leakage part is sealed with the sealing plate 27 to reduce environmental interference.

[0041] After the needle 21 is pulled out, the connector 16 can be rotated above the metal tube 20 and pressed down so that its end is connected to the metal tube 20. At the same time, the end of the connector 16 is fixed with the sealing plate 27 to complete the seal. By connecting the injection tube 4 to the injection valve 26, the slow drug delivery can be completed.

[0042] The foregoing has shown and described the basic principles, main features, and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The embodiments and descriptions in the specification are merely illustrative of the principles of the invention. Various changes and modifications can be made to the invention without departing from its spirit and scope, and all such changes and modifications fall within the scope of the present invention as claimed. The scope of protection of the present invention is defined by the appended claims and their equivalents.

Claims

1. A drug delivery device for rheumatic immune diseases, characterized in that: The device includes an auxiliary sleeve, a stop seat in the middle of the auxiliary sleeve, a top block fixed to the top of the auxiliary sleeve for controlling the stop seat to push downward, an injection needle at the bottom of the stop seat, a communicating device for communicating with the injection needle at the top of the stop seat, an adding base at the bottom of the auxiliary sleeve, an adhesive piece placed on top of the adding base, a connecting ring attached to the top surface of the adhesive piece near its edge, and the connecting ring connected to the bottom of the auxiliary sleeve. The injection needle includes a metal tube and a needle tube wrapped around the outside of the metal tube. A protective sleeve is threaded to the bottom of the stop seat. The protective sleeve is located outside the needle tube. A drive wheel for pulling the needle tube upward is provided in the stop seat. The needle tube has an opening on the outside and a pointed bottom that extends beyond the bottom of the metal tube. The outer side of the drive wheel is in contact with the outer side of the needle tube, and the top of the needle tube extends through to the top of the rest seat. The inside of the stop seat is fixedly connected to a storage box, and the outside of the storage box is connected to a metal tube through multiple pipes. The other side of the needle tube is provided with a squeezing plate that can be moved horizontally. The dwell seat is internally fixed with a sliding lock box. Multiple sliding rods are slidably connected to one end of the sliding lock box facing the needle tube. The sliding rods are fixedly connected to the extrusion plate. An auxiliary frame is fixedly connected to the top of the sliding rods. The auxiliary frame is drivenly connected to the bottom of the drive wheel. The auxiliary frame is slidably connected to the top of the storage box and the sliding lock box. During the needle removal process, the drive wheel is activated first. The drive wheel simultaneously contacts the auxiliary frame and the outside of the needle. Under the action of friction, the needle moves upward. At the same time, the auxiliary frame and the squeezing plate move towards the storage box. The squeezing plate will squeeze the needle first, but the curvature of the two is not matched, and the contact surface is small. This will not affect the needle's continued upward movement. After the needle is removed, the squeezing plate continues to move and will contact the metal tube. At this time, the slide bar slides to its limit position. The elastic element inside the slide lock box is used to block the slide bar when it slides to its limit, preventing it from moving. In this way, the metal tube will be restricted by the tube and the squeezing plate, keeping it in a vertical state, while allowing the needle to be removed smoothly.

2. The drug delivery device for rheumatic immune diseases according to claim 1, characterized in that: The auxiliary sleeve has two sets of binding plates fixed inside, both sets of binding plates are arranged in a ring, the binding plates are made of elastic material, the top surface of the connecting ring has multiple mating holes, and the bottom of the auxiliary sleeve has multiple mating blocks that are adapted to the mating holes.

3. The drug delivery device for rheumatic immune diseases according to claim 2, characterized in that: The top of the top platform is equipped with a control button and a filling valve. Two jet heads are fixed to the bottom of the top platform. The edge of the stop seat is movably fitted with the inner wall of the auxiliary sleeve. Multiple side grooves are opened on the outer side of the auxiliary sleeve, and injection tubes are placed in the side grooves.

4. The drug delivery device for rheumatic immune diseases according to claim 3, characterized in that: The storage box is filled with liquid, and the metal tube has a hollow design that runs through the top and bottom, with multiple grooves on the surface of the metal tube.

5. A drug delivery device for rheumatic immune diseases according to claim 4, characterized in that: The top surface of the stop seat has a slot, in which a power box for controlling the rotation of the drive wheel is placed. A protrusion to assist in removal is fixed to the top of the stop seat, and two closed plates are slidably connected to the top surface of the stop seat.

6. The drug delivery device for rheumatic immune diseases according to claim 5, characterized in that: The communicating vessel is rotatably connected to the top surface of the stop seat. An injection valve is fixedly connected to the top surface of the communicating vessel, and a docking valve for communicating with a metal pipe is fixedly connected to the bottom surface of the injection valve.

Images